US 2026/0061022 A1Published application

Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same

AssigneeGi Innovation, Inc.

InventorsMyoung Ho JANG, Bo-Gie YANG, Kyungwha LEE

Life of this patent

Estimating the term…

Loading patent…

Abstract

A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.

Claims13

Dependent claims

A method for preventing and/or treating an allergic disease in a subject in need thereof, comprising administering an effective amount of a polypeptide dimer or a composition comprising the polypeptide dimer, to the subject,

wherein the polypeptide dimer comprising:
a first monomer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIα-ECD),
a second monomer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIα-ECD),
wherein the first monomer and the second monomer each contain an Fc region, and
wherein the Fc region and the FcεRIα-ECD, in the first and second monomers, are linked via a hinge, and
wherein the polypeptide dimer comprises sialic acid and a molar ratio of the sialic acid to the polypeptide dimer is at least 8.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/294,769Filed 8 Aug 2025
Priority: KR 10-2019-00822178 Jul 2019
Published: 5 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 38/00
Medicinal preparations containing peptides
A23L 33/18
Amino acids, peptides or proteins: peptides; Protein hydrolysates
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/7023
Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug: transdermal patches and similar drug-containing composite…

Family

Application17/625,668Division
Application19/294,769Division
US 12,409,203 B2Related patent
US 2022/0257693 A1Published application
US 2026/0061022 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key